{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:58:54Z","timestamp":1790384334789,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-00997-x","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:38:11Z","timestamp":1783618691000},"page":"2393-2415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Role of Early Add-On Cenobamate in Uncontrolled Focal Epilepsy: A Critical Appraisal of the Evidence"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-0083","authenticated-orcid":false,"given":"Simona","family":"Lattanzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Andrea","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Iudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Di Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"8","key":"997_CR1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S1474-4422(23)00151-5","volume":"22","author":"E Perucca","year":"2023","unstructured":"Perucca E, Perucca P, White HS, Wirrell EC. Drug resistance in epilepsy. Lancet Neurol. 2023;22(8):723\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(23)00151-5.","journal-title":"Lancet Neurol"},{"issue":"3","key":"997_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279\u201386. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3949.","journal-title":"JAMA Neurol"},{"issue":"3","key":"997_CR3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/epi4.70021","volume":"10","author":"S Rheims","year":"2025","unstructured":"Rheims S, Steinhoff BJ, Hirsch E, Rosenow F, Biraben A, Thomas R, et al. Real-world effectiveness and tolerability of cenobamate in drug-resistant epilepsy: a retrospective analysis of the patients included into the early access programs (EAP) in Germany, France, and United Kingdom. Epilepsia Open. 2025;10(3):736\u201348. https:\/\/doi.org\/10.1002\/epi4.70021.","journal-title":"Epilepsia Open"},{"issue":"6","key":"997_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.5603\/pjnns.97121","volume":"57","author":"A Lasek-Bal","year":"2023","unstructured":"Lasek-Bal A, Ksciuk B, Zielinski T, Krzak-Kubica A, Kowalski J, Zorniak-Milach B, et al. Long-term cenobamate retention, efficacy, and safety: outcomes from Expanded Access Programme. Neurol Neurochir Pol. 2023;57(6):492\u20136. https:\/\/doi.org\/10.5603\/pjnns.97121.","journal-title":"Neurol Neurochir Pol."},{"issue":"5","key":"997_CR5","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1111\/epi.18297","volume":"66","author":"I Loushy","year":"2025","unstructured":"Loushy I, Goldstein L, Devlin K, Volski A, Fletman E, Alcala-Zermeno JL, et al. Real-world use of cenobamate in adults: efficacy and predictors of treatment response. Epilepsia. 2025;66(5):1492\u2013504. https:\/\/doi.org\/10.1111\/epi.18297.","journal-title":"Epilepsia"},{"key":"997_CR6","doi-asserted-by":"publisher","first-page":"117957352110702","DOI":"10.1177\/11795735211070209","volume":"14","author":"A Singh","year":"2022","unstructured":"Singh A. Cenobamate for treatment-resistant focal seizures: current evidence and place in therapy. J Cent Nerv Syst Dis. 2022;14:11795735211070208. https:\/\/doi.org\/10.1177\/11795735211070209.","journal-title":"J Cent Nerv Syst Dis."},{"key":"997_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.seizure.2025.11.010","volume":"134","author":"R Sankar","year":"2025","unstructured":"Sankar R, Ferrari L, Kamin M. Exploration of the mechanism of action of cenobamate. Seizure. 2025;134:79\u201385. https:\/\/doi.org\/10.1016\/j.seizure.2025.11.010.","journal-title":"Seizure"},{"issue":"6","key":"997_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40263-021-00819-8","volume":"35","author":"R Roberti","year":"2021","unstructured":"Roberti R, De Caro C, Iannone LF, Zaccara G, Lattanzi S, Russo E. Pharmacology of cenobamate: mechanism of action, pharmacokinetics, drug-drug interactions and tolerability. CNS Drugs. 2021;35(6):609\u201318. https:\/\/doi.org\/10.1007\/s40263-021-00819-8.","journal-title":"CNS Drugs"},{"issue":"2","key":"997_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","volume":"82","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S, Trinka E, Zaccara G, Striano P, Russo E, Del Giovane C, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs. 2022;82(2):199\u2013218. https:\/\/doi.org\/10.1007\/s40265-021-01661-4.","journal-title":"Drugs"},{"issue":"4","key":"997_CR10","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40120-025-00781-3","volume":"14","author":"A Labate","year":"2025","unstructured":"Labate A, Liguori C, Tartara E, Tumminelli G, Nilo A, Piccioli M, et al. Early introduction of cenobamate in uncontrolled focal epilepsy: insights from a structured controversy. Neurol Ther. 2025;14(4):1671\u201384. https:\/\/doi.org\/10.1007\/s40120-025-00781-3.","journal-title":"Neurol Ther"},{"issue":"1","key":"997_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38\u201348. https:\/\/doi.org\/10.1016\/S1474-4422(19)30399-0.","journal-title":"Lancet Neurol."},{"issue":"22","key":"997_CR12","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322. https:\/\/doi.org\/10.1212\/WNL.0000000000009530.","journal-title":"Neurology"},{"issue":"2","key":"997_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40263-024-01063-6","volume":"38","author":"PJ Serrano-Castro","year":"2024","unstructured":"Serrano-Castro PJ, Ramirez-Garcia T, Cabezudo-Garcia P, Garcia-Martin G, De La Parra J. Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study. CNS Drugs. 2024;38(2):141\u201351. https:\/\/doi.org\/10.1007\/s40263-024-01063-6.","journal-title":"CNS Drugs"},{"key":"997_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1239152","volume":"14","author":"N Pietrafusa","year":"2023","unstructured":"Pietrafusa N, Falcicchio G, Russo E, Lattanzi S, Goffredo B, Simeoli R, et al. Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence? Front Pharmacol. 2023;14:1239152. https:\/\/doi.org\/10.3389\/fphar.2023.1239152.","journal-title":"Front Pharmacol"},{"key":"997_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.seizure.2024.04.004","volume":"118","author":"S Mulheron","year":"2024","unstructured":"Mulheron S, Leahy TP, McStravick M, Doran R, Delanty N. A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: a systematic review and network meta-analysis. Seizure. 2024;118:80\u201390. https:\/\/doi.org\/10.1016\/j.seizure.2024.04.004.","journal-title":"Seizure"},{"issue":"1","key":"997_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/epi4.12857","volume":"9","author":"J Catalan-Aguilar","year":"2024","unstructured":"Catalan-Aguilar J, Hampel KG, Cano-Lopez I, Garces M, Lozano-Garcia A, Tormos-Pons P, et al. Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy. Epilepsia Open. 2024;9(1):223\u201335. https:\/\/doi.org\/10.1002\/epi4.12857.","journal-title":"Epilepsia Open"},{"issue":"7650","key":"997_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"4","key":"997_CR18","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/epi4.12997","volume":"9","author":"H Zhang","year":"2024","unstructured":"Zhang H, Ou Z, Zhang E, Liu W, Hao N, Chen Y, et al. Efficacy and safety of add-on antiseizure medications for focal epilepsy: a network meta-analysis. Epilepsia Open. 2024;9(4):1550\u201364. https:\/\/doi.org\/10.1002\/epi4.12997.","journal-title":"Epilepsia Open"},{"key":"997_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf238","author":"K Xie","year":"2025","unstructured":"Xie K, Korzun J, Zhou DJ, Chang E, Ghosn NJ, Lavelle S, et al. Comparative effectiveness of anti-seizure medications in emulated trials using medical informatics. Brain. 2025. https:\/\/doi.org\/10.1093\/brain\/awaf238.","journal-title":"Brain"},{"issue":"9","key":"997_CR20","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40263-024-01109-9","volume":"38","author":"Y Winter","year":"2024","unstructured":"Winter Y, Abou Dargham R, Patino Tobon S, Groppa S, Fuest S. Cenobamate as an early adjunctive treatment in drug-resistant focal-onset seizures: an observational cohort study. CNS Drugs. 2024;38(9):733\u201342. https:\/\/doi.org\/10.1007\/s40263-024-01109-9.","journal-title":"CNS Drugs"},{"key":"997_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.109054","volume":"139","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Serratosa JM, Toledo M, Angel Calleja M, Navarro A, Sabaniego J, et al. Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain. Epilepsy Behav. 2023;139:109054. https:\/\/doi.org\/10.1016\/j.yebeh.2022.109054.","journal-title":"Epilepsy Behav"},{"key":"997_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108679","volume":"130","author":"RT Varughese","year":"2022","unstructured":"Varughese RT, Shah YD, Karkare S, Kothare SV. Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: a single-center retrospective study. Epilepsy Behav. 2022;130:108679. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108679.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"997_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40263-025-01158-8","volume":"39","author":"A Strzelczyk","year":"2025","unstructured":"Strzelczyk A, von Podewils F, Hamer HM, Knake S, Rosenow F, Klotz KA, et al. Post-marketing experience with cenobamate in the treatment of focal epilepsies: a multicentre cohort study. CNS Drugs. 2025;39(3):321\u201331. https:\/\/doi.org\/10.1007\/s40263-025-01158-8.","journal-title":"CNS Drugs."},{"issue":"4","key":"997_CR24","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/epi4.12992","volume":"9","author":"BJ Steinhoff","year":"2024","unstructured":"Steinhoff BJ, Georgiou D, Intravooth T. The cenobamate KORK study-A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and brivaracetam. Epilepsia Open. 2024;9(4):1502\u201314. https:\/\/doi.org\/10.1002\/epi4.12992.","journal-title":"Epilepsia Open"},{"issue":"5","key":"997_CR25","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/epi.17549","volume":"64","author":"J Pena-Ceballos","year":"2023","unstructured":"Pena-Ceballos J, Moloney PB, Munteanu T, Doyle M, Colleran N, Liggan B, et al. Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a \u201creal-world\u201d retrospective study. Epilepsia. 2023;64(5):1225\u201335. https:\/\/doi.org\/10.1111\/epi.17549.","journal-title":"Epilepsia"},{"issue":"3","key":"997_CR26","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/epi.17874","volume":"65","author":"Y Novitskaya","year":"2024","unstructured":"Novitskaya Y, Schutz E, Metternich B, Schulze-Bonhage A, Hirsch M. Add-on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: a prospective observational study. Epilepsia. 2024;65(3):630\u201340. https:\/\/doi.org\/10.1111\/epi.17874.","journal-title":"Epilepsia"},{"issue":"4","key":"997_CR27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s40120-024-00634-5","volume":"13","author":"S Lattanzi","year":"2024","unstructured":"Lattanzi S, Ranzato F, Di Bonaventura C, Bonanni P, Gambardella A, Tartara E, et al. Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: evidence from the first interim analysis of the BLESS study. Neurol Ther. 2024;13(4):1203\u201317. https:\/\/doi.org\/10.1007\/s40120-024-00634-5.","journal-title":"Neurol Ther"},{"key":"997_CR28","doi-asserted-by":"publisher","unstructured":"Lattanzi S, Dono F, d'Orsi G, D'Aniello A, Panebianco M, Bonanni P, Di Bonaventura C, Montalenti E, Gambardella A, Ranzato F, Pauletto G, Tartara E, La Neve A, Bisulli F, Vatti G, Pulitano P, Liguori C, Assenza G, Giordano A, Pignatta P, Belcastro V, Cecconi M, Beretta S, Pizzanelli C, Pezzella M, Gangitano M, Elia M, Renna R, Vollono C, Pascarella A, Tramacere L, De Maria G, Audenino D, Pasolini MP, Giuliano L, Galli R, Strigaro G, Puligheddu M, Labate A, Penza P, Quadri S, Stokelj D, Boero G, Fallica E, Santo Sabato M, Falcicchio G, Foschi N, Procaccini M, Villano V, Camattari G, Mele F, Roncari B, Di Gennaro G, Group BS. Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: Interim results after 24-week observational period from the BLESS study. Epilepsia. 2025;66(7):2239\u201352. https:\/\/doi.org\/10.1111\/epi.18357","DOI":"10.1111\/epi.18357"},{"key":"997_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109350","volume":"145","author":"M Falip","year":"2023","unstructured":"Falip M, Lopez Gonzalez FJ, Martin-Herranz I, Merino-Bohorquez V, Montoya J, Rey Gomez-Serranillos I, et al. Value contribution of cenobamate for the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective multi-criteria decision analysis (MCDA). Epilepsy Behav. 2023;145:109350. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109350.","journal-title":"Epilepsy Behav"},{"key":"997_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102513","volume":"70","author":"Y Chen","year":"2024","unstructured":"Chen Y, Li W, Lu C, Gao X, Song H, Zhang Y, et al. Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials. EClinicalMedicine. 2024;70:102513. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102513.","journal-title":"EClinicalMedicine"},{"issue":"8","key":"997_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014941.pub2","volume":"8","author":"F Brigo","year":"2024","unstructured":"Brigo F, Lattanzi S. Cenobamate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2024;8(8):CD014941. https:\/\/doi.org\/10.1002\/14651858.CD014941.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"997_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.seizure.2025.05.002","volume":"130","author":"M Bosak","year":"2025","unstructured":"Bosak M, Podraza H, Wloch-Kopec D, Rysz A, Wezyk K, Grabska-Radzikowska K, et al. Efficacy and safety of Cenobamate: a multicenter, retrospective evaluation of real-world clinical practice. Seizure. 2025;130:25\u201331. https:\/\/doi.org\/10.1016\/j.seizure.2025.05.002.","journal-title":"Seizure."},{"key":"997_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1307296","volume":"14","author":"Y Yang","year":"2023","unstructured":"Yang Y, Shangguan Y, Wang X, Liu R, Shen Z, Tang M, et al. The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: a systematic review and network meta-analysis study. Front Neurol. 2023;14:1307296. https:\/\/doi.org\/10.3389\/fneur.2023.1307296.","journal-title":"Front Neurol"},{"key":"997_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109653","volume":"152","author":"J Tong","year":"2024","unstructured":"Tong J, Ji T, Liu T, Liu J, Chen Y, Li Z, et al. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: a systematic review and network meta-analysis. Epilepsy Behav. 2024;152:109653. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109653.","journal-title":"Epilepsy Behav"},{"key":"997_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107207","volume":"197","author":"S Stern","year":"2023","unstructured":"Stern S, Weingarten M, Mandapati S, Ferrari L, Wade CT. Real-world analysis of retention on cenobamate in patients with epilepsy in the United States. Epilepsy Res. 2023;197:107207. https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107207.","journal-title":"Epilepsy Res"},{"key":"997_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108429","volume":"126","author":"M Privitera","year":"2022","unstructured":"Privitera M, Richy FF, Schabert VF. Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. Epilepsy Behav. 2022;126:108429. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108429.","journal-title":"Epilepsy Behav"},{"issue":"Suppl 2","key":"997_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.33393\/grhta.2022.2420","volume":"9","author":"S Lattanzi","year":"2022","unstructured":"Lattanzi S. New evidence in adjunctive treatment of focal-onset seizures in adults: a critical appraisal. Glob Reg Health Technol Assess. 2022;9(Suppl 2):14\u20139. https:\/\/doi.org\/10.33393\/grhta.2022.2420.","journal-title":"Glob Reg Health Technol Assess"},{"key":"997_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.33393\/grhta.2025.3341","volume":"12","author":"M Paoletti","year":"2025","unstructured":"Paoletti M, Ragonese A, Budassi L, Marcellusi A. Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure control. Glob Reg Health Technol Assess. 2025;12:118\u201329. https:\/\/doi.org\/10.33393\/grhta.2025.3341.","journal-title":"Glob Reg Health Technol Assess"},{"key":"997_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2025.100799","volume":"31","author":"A Zillgitt","year":"2025","unstructured":"Zillgitt A, Burdette DE, Yako A, Rashingkar R, Terrell A, Jacobs S, et al. Synergistic seizure reduction in patient with persistently elevated N-desmethylclobazam levels, CYP450 genetic polymorphism, and responsive neurostimulator targeting centromedian nuclei of bilateral thalami. Epilepsy Behav Rep. 2025;31:100799. https:\/\/doi.org\/10.1016\/j.ebr.2025.100799.","journal-title":"Epilepsy Behav Rep."},{"key":"997_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241256733","volume":"17","author":"BJ Steinhoff","year":"2024","unstructured":"Steinhoff BJ, Ben-Menachem E, Klein P, Peltola J, Schmitz B, Thomas RH, et al. Therapeutic strategies during cenobamate treatment initiation: Delphi panel recommendations. Ther Adv Neurol Disord. 2024;17:17562864241256733. https:\/\/doi.org\/10.1177\/17562864241256733.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"997_CR41","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","volume":"11","author":"MC Smith","year":"2022","unstructured":"Smith MC, Klein P, Krauss GL, Rashid S, Seiden LG, Stern JM, et al. Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations. Neurol Ther. 2022;11(4):1705\u201320. https:\/\/doi.org\/10.1007\/s40120-022-00400-5.","journal-title":"Neurol Ther"},{"issue":"12","key":"997_CR42","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1111\/epi.17092","volume":"62","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Krauss GL, et al. Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia. 2021;62(12):3016\u201328. https:\/\/doi.org\/10.1111\/epi.17092.","journal-title":"Epilepsia"},{"issue":"4","key":"997_CR43","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1002\/epi4.12959","volume":"9","author":"JJ Rodriguez-Uranga","year":"2024","unstructured":"Rodriguez-Uranga JJ, Sanchez-Caro JM, Hariramani Ramchandani R. Treatment simplification to optimize cenobamate effectiveness and tolerability: a real-world retrospective study in Spain. Epilepsia Open. 2024;9(4):1345\u201356. https:\/\/doi.org\/10.1002\/epi4.12959.","journal-title":"Epilepsia Open"},{"issue":"10","key":"997_CR44","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1111\/epi.18091","volume":"65","author":"R Roberti","year":"2024","unstructured":"Roberti R, Assenza G, Bisulli F, Boero G, Canafoglia L, Chiesa V, et al. Adjunctive cenobamate in people with focal onset seizures: insights from the Italian expanded access program. Epilepsia. 2024;65(10):2909\u201322. https:\/\/doi.org\/10.1111\/epi.18091.","journal-title":"Epilepsia"},{"issue":"10","key":"997_CR45","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1007\/s00415-024-12510-1","volume":"271","author":"S Lauxmann","year":"2024","unstructured":"Lauxmann S, Heuer D, Heckelmann J, Fischer FP, Schreiber M, Schriewer E, et al. Cenobamate: real-world data from a retrospective multicenter study. J Neurol. 2024;271(10):6596\u2013604. https:\/\/doi.org\/10.1007\/s00415-024-12510-1.","journal-title":"J Neurol"},{"key":"997_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27217325","author":"B Charlier","year":"2022","unstructured":"Charlier B, Coglianese A, Operto FF, Coppola G, de Grazia U, Menna P, et al. Development and validation of a UHPLC-MS\/MS-based method to quantify cenobamate in human plasma samples. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27217325.","journal-title":"Molecules"},{"issue":"3","key":"997_CR47","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/epi4.12936","volume":"9","author":"M Carreno","year":"2024","unstructured":"Carreno M, Gil-Nagel A, Serratosa JM, Toledo M, Rodriguez-Uranga JJ, Villanueva V. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures. Epilepsia Open. 2024;9(3):1051\u20138. https:\/\/doi.org\/10.1002\/epi4.12936.","journal-title":"Epilepsia Open"},{"issue":"5","key":"997_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70567","volume":"15","author":"M Badr","year":"2025","unstructured":"Badr M, Helmstaedter C, Moskau-Hartmann S, Pukropski J, Witt JA, Ruber T, et al. Cenobamate in real-word scenario: results on efficacy, side effects, and retention rate in a single center retrospective study. Brain Behav. 2025;15(5):e70567. https:\/\/doi.org\/10.1002\/brb3.70567.","journal-title":"Brain Behav."},{"issue":"3","key":"997_CR49","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/epi4.12757","volume":"8","author":"V Villanueva","year":"2023","unstructured":"Villanueva V, Santos-Carrasco D, Cabezudo-Garcia P, Gomez-Ibanez A, Garces M, Serrano-Castro P, et al. Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an expanded access program. Epilepsia Open. 2023;8(3):918\u201329. https:\/\/doi.org\/10.1002\/epi4.12757.","journal-title":"Epilepsia Open"},{"issue":"3","key":"997_CR50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40266-024-01102-3","volume":"41","author":"R O'Dwyer","year":"2024","unstructured":"O\u2019Dwyer R, Stern S, Wade CT, Guggilam A, Rosenfeld WE. Safety and efficacy of cenobamate for the treatment of focal seizures in older patients: post hoc analysis of a phase III, multicentrer, open-label study. Drugs Aging. 2024;41(3):251\u201360. https:\/\/doi.org\/10.1007\/s40266-024-01102-3.","journal-title":"Drugs Aging."},{"key":"997_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1558614","volume":"16","author":"PM House","year":"2025","unstructured":"House PM, Wiese L. Real-world utilization of cenobamate as adjunct therapy in office-based neurology: practical tips and insights for titration. Front Neurol. 2025;16:1558614. https:\/\/doi.org\/10.3389\/fneur.2025.1558614.","journal-title":"Front Neurol"},{"issue":"8","key":"997_CR52","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1007\/s10072-025-08174-y","volume":"46","author":"CE Gjerulfsen","year":"2025","unstructured":"Gjerulfsen CE, Juhl S, Mieszczanek KM, Spanila L, Thygesen KS, Pavbro A, et al. Cenobamate as add-on treatment in ultra-refractory focal epilepsy: real-world results from The Danish Epilepsy Centre, Dianalund, Denmark. Neurol Sci. 2025;46(8):3875\u201384. https:\/\/doi.org\/10.1007\/s10072-025-08174-y.","journal-title":"Neurol Sci."},{"key":"997_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2022.100533","volume":"18","author":"GS Connor","year":"2022","unstructured":"Connor GS, Williamson A. Effectiveness and safety of adjunctive cenobamate for focal seizures in adults with developmental disability treated in clinical practice. Epilepsy Behav Rep. 2022;18:100533. https:\/\/doi.org\/10.1016\/j.ebr.2022.100533.","journal-title":"Epilepsy Behav Rep."},{"key":"997_CR54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.seizure.2025.05.011","volume":"131","author":"MJ Aguilar-Amat Prior","year":"2025","unstructured":"Aguilar-Amat Prior MJ, Alonso Singer P, Oliva Navarro J, Olivie Garcia L, Machio Castello M, Beltran-Corbellini A, et al. Effectiveness and safety of cenobamate in Lennox-Gastaut syndrome: a multicenter real-world study in Spain. Seizure. 2025;131:84\u20139. https:\/\/doi.org\/10.1016\/j.seizure.2025.05.011.","journal-title":"Seizure"},{"key":"997_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2024.107306","volume":"200","author":"S Aboumatar","year":"2024","unstructured":"Aboumatar S, Ferrari L, Stern S, Wade CT, Weingarten M, Connor GS, et al. Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: post hoc analysis of a subset of patients from a phase 3, multicenter, open-label study. Epilepsy Res. 2024;200:107306. https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107306.","journal-title":"Epilepsy Res"},{"key":"997_CR56","unstructured":"Bertolini C, Di Liberto A, Rossi GB, Novara A, Viglietta E, Vitale C, et al. Cenobamato nell\u2019epilessia focale: uno studio retrospettivo multicentrico di real world dal Gruppo Epi-To. In: 47\u00b0 Congresso Nazionale LICE; 2024 Jun 5\u20136; Rome, Italy. Lega Italiana Contro l\u2019Epilessia; 2024. Abstract T4\u2013077."},{"key":"997_CR57","unstructured":"Ranzato F, Zivelonghi C, Dainese F, Danieli A, Peretti A, Zanoni T, et al. Real-world use of cenobamate (CNB): a multicenter Italian experience. In: 35th international epilepsy congress (IEC 2023); 2023 Sep 2\u20136; Dublin, Ireland. International League Against Epilepsy; 2023. Abstract 1533."},{"key":"997_CR58","doi-asserted-by":"publisher","DOI":"10.1111\/epi.70006","author":"JM Sanchez-Caro","year":"2025","unstructured":"Sanchez-Caro JM, Hariramani Ramchandani R, Maestro Saiz I, Rodriguez Uranga JJ. Impact of long-term treatment with cenobamate on concomitant usage of antiseizure medications: a real-world retrospective study in Spain. Epilepsia. 2025. https:\/\/doi.org\/10.1111\/epi.70006.","journal-title":"Epilepsia"},{"key":"997_CR59","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00859-y","author":"T Ramirez-Garcia","year":"2025","unstructured":"Ramirez-Garcia T, Cabezudo-Garcia P, Garcia-Martin G, Lopez-Moreno Y, Sanchez-Guijo A, De La Parra J, et al. Long-term impact of cenobamate on cognition in patients with drug-resistant focal epilepsy: outcomes from an exploratory real-world study. Neurol Ther. 2025. https:\/\/doi.org\/10.1007\/s40120-025-00859-y.","journal-title":"Neurol Ther"},{"key":"997_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1625612","volume":"16","author":"S Shang","year":"2025","unstructured":"Shang S, Chen D, Song Z, Zhou C, Chang Q, Xiang L, et al. Real-world safety comparison between cenobamate and lacosamide: a pharmacovigilance study based on the FDA adverse event reporting system. Front Neurol. 2025;16:1625612. https:\/\/doi.org\/10.3389\/fneur.2025.1625612.","journal-title":"Front Neurol"},{"key":"997_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2023.09.006","volume":"112","author":"KL Makridis","year":"2023","unstructured":"Makridis KL, Kaindl AM. Real-world experience with cenobamate: a systematic review and meta-analysis. Seizure. 2023;112:1\u201310. https:\/\/doi.org\/10.1016\/j.seizure.2023.09.006.","journal-title":"Seizure"},{"issue":"9","key":"997_CR62","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1001\/jamaneurol.2021.2480","volume":"78","author":"P Klein","year":"2021","unstructured":"Klein P, Devinsky O, French J, Harden C, Krauss GL, McCarter R, et al. Suicidality risk of newer antiseizure medications: a meta-analysis. JAMA Neurol. 2021;78(9):1118\u201327. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2480.","journal-title":"JAMA Neurol"},{"issue":"3","key":"997_CR63","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1177\/1060028020941113","volume":"55","author":"CT Buckley","year":"2021","unstructured":"Buckley CT, Waters OR, DeMaagd G. Cenobamate: a new adjunctive agent for drug-resistant focal onset epilepsy. Ann Pharmacother. 2021;55(3):318\u201329. https:\/\/doi.org\/10.1177\/1060028020941113.","journal-title":"Ann Pharmacother."},{"key":"997_CR64","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.seizure.2022.02.003","volume":"96","author":"C Brandt","year":"2022","unstructured":"Brandt C, Sanchez-Alvarez JC, Steinhoff BJ, Milanov I, Serratosa JM. Efficacy and safety of adjunctive cenobamate: post hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications. Seizure. 2022;96:86\u201393. https:\/\/doi.org\/10.1016\/j.seizure.2022.02.003.","journal-title":"Seizure"},{"key":"997_CR65","doi-asserted-by":"publisher","unstructured":"Blaszczyk B, Czuczwar SJ, Miziak B. Cenobamate, a New Promising Antiseizure Medication: Experimental and Clinical Aspects. Int J Mol Sci. 2024;25(23).https:\/\/doi.org\/10.3390\/ijms252313014","DOI":"10.3390\/ijms252313014"},{"key":"997_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1571376","volume":"16","author":"L Bender","year":"2025","unstructured":"Bender L, Hirsch M, Schulze-Bonhage A. Increase of brivaracetam serum concentration with introduction of cenobamate. Front Pharmacol. 2025;16:1571376. https:\/\/doi.org\/10.3389\/fphar.2025.1571376.","journal-title":"Front Pharmacol"},{"key":"997_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2025.110722","volume":"172","author":"J Li","year":"2025","unstructured":"Li J, Zhong R, Zhang F, Guo Y. Psychiatric disorders associated with newer antiseizure medications: a real-world disproportionality analysis of FDA adverse event reporting system. Epilepsy Behav. 2025;172:110722. https:\/\/doi.org\/10.1016\/j.yebeh.2025.110722.","journal-title":"Epilepsy Behav"},{"key":"997_CR68","doi-asserted-by":"publisher","unstructured":"Bekenova N, Aitkaliyev A, Kassiyeva B, Vochshenkova T, Suleimenova A, Kimadiyev D. EpiTrack: direct and indirect role in the assessment of executive functions and memory\u2014systematic review. Appl Neuropsychol Adult. 2025:1\u201310. https:\/\/doi.org\/10.1080\/23279095.2025.2592882","DOI":"10.1080\/23279095.2025.2592882"},{"issue":"1","key":"997_CR69","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/epi.17134","volume":"63","author":"JW Sander","year":"2022","unstructured":"Sander JW, Rosenfeld WE, Halford JJ, Steinhoff BJ, Biton V, Toledo M. Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program. Epilepsia. 2022;63(1):139\u201349. https:\/\/doi.org\/10.1111\/epi.17134.","journal-title":"Epilepsia"},{"issue":"9","key":"997_CR70","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/epi.17007","volume":"62","author":"JA French","year":"2021","unstructured":"French JA, Chung SS, Krauss GL, Lee SK, Maciejowski M, Rosenfeld WE, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Epilepsia. 2021;62(9):2142\u201350. https:\/\/doi.org\/10.1111\/epi.17007.","journal-title":"Epilepsia"},{"key":"997_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13102757","author":"BJ Steinhoff","year":"2024","unstructured":"Steinhoff BJ, Georgiou D, Dietmann D, Intravooth T. Cenobamate plasma levels in patients with epilepsy: correlation with efficacy and tolerability? J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13102757.","journal-title":"J Clin Med"},{"issue":"3","key":"997_CR72","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/ane.13659","volume":"146","author":"BJ Steinhoff","year":"2022","unstructured":"Steinhoff BJ, Ben-Menachem E, Brandt C, Garcia Morales I, Rosenfeld WE, Santamarina E, et al. Onset of efficacy and adverse events during cenobamate titration period. Acta Neurol Scand. 2022;146(3):265\u201375. https:\/\/doi.org\/10.1111\/ane.13659.","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"997_CR73","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40263-025-01166-8","volume":"39","author":"R Roberti","year":"2025","unstructured":"Roberti R, Di Gennaro G, Cianci V, D\u2019Aniello A, Di Bonaventura C, Di Gennaro G, et al. Exploring the effectiveness of adjunctive cenobamate in focal epilepsy: a time-based analysis. CNS Drugs. 2025;39(5):513\u201323. https:\/\/doi.org\/10.1007\/s40263-025-01166-8.","journal-title":"CNS Drugs."},{"issue":"Suppl 1","key":"997_CR74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/epi.18304","volume":"66","author":"GL Krauss","year":"2025","unstructured":"Krauss GL, Sander JW, Rosenfeld WE. Improving the tolerability of antiseizure medications: when and how to use cenobamate and other new antiseizure medications. Epilepsia. 2025;66(Suppl 1):15\u201328. https:\/\/doi.org\/10.1111\/epi.18304.","journal-title":"Epilepsia"},{"key":"997_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1209487","volume":"14","author":"AL Friedo","year":"2023","unstructured":"Friedo AL, Greshake B, Makridis KL, Straub HB. Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction. Front Neurol. 2023;14:1209487. https:\/\/doi.org\/10.3389\/fneur.2023.1209487.","journal-title":"Front Neurol"},{"key":"997_CR76","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2023.07.026","volume":"111","author":"A Beltran-Corbellini","year":"2023","unstructured":"Beltran-Corbellini A, Romeral-Jimenez M, Mayo P, Sanchez-Miranda Roman I, Iruzubieta P, Chico-Garcia JL, et al. Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study. Seizure. 2023;111:71\u20137. https:\/\/doi.org\/10.1016\/j.seizure.2023.07.026.","journal-title":"Seizure"},{"issue":"6","key":"997_CR77","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099\u2013108. https:\/\/doi.org\/10.1111\/epi.16525.","journal-title":"Epilepsia"},{"key":"997_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106592","volume":"172","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Nisman A, Ferrari L. Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post hoc analysis of a randomized clinical study. Epilepsy Res. 2021;172:106592. https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106592.","journal-title":"Epilepsy Res."},{"key":"997_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107185","volume":"195","author":"V Vashi","year":"2023","unstructured":"Vashi V, Rosenfeld WE, Ferrari L, Kamin M. Pharmacokinetics of cenobamate as monotherapy compared with adjunctive therapy. Epilepsy Res. 2023;195:107185. https:\/\/doi.org\/10.1016\/j.eplepsyres.2023.107185.","journal-title":"Epilepsy Res."},{"key":"997_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176222","volume":"962","author":"A Leo","year":"2024","unstructured":"Leo A, Bosco F, Guarnieri L, De Sarro C, Rania V, Gallelli L, et al. Cenobamate enhances the anticonvulsant effect of other antiseizure medications in the DBA\/2 mouse model of reflex epilepsy. Eur J Pharmacol. 2024;962:176222. https:\/\/doi.org\/10.1016\/j.ejphar.2023.176222.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"997_CR81","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/cts.13204","volume":"15","author":"SA Greene","year":"2022","unstructured":"Greene SA, Kwak C, Kamin M, Vernillet L, Glenn KJ, Gabriel L, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. Clin Transl Sci. 2022;15(4):899\u2013911. https:\/\/doi.org\/10.1111\/cts.13204.","journal-title":"Clin Transl Sci"},{"key":"997_CR82","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pediatrneurol.2024.08.009","volume":"161","author":"LL Becker","year":"2024","unstructured":"Becker LL, Agricola K, Ritter DM, Krueger DA, Franz DN. Mammalian target of rapamycin inhibitor levels decrease under cenobamate treatment. Pediatr Neurol. 2024;161:73\u20135. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.08.009.","journal-title":"Pediatr Neurol"},{"key":"997_CR83","unstructured":"Jimenez AOC, Nuthalapati P, Toghramadjian I, Dorotan M, Altalib H, Hirsch L, Herlopian A. Drug\u2013drug interactions between cenobamate and other concomitantly administered medications. In: American Epilepsy Society (AES) 2024 Annual Meeting; 2024 Dec 6\u201310; Los Angeles, CA, USA. American Epilepsy Society; 2024. Abstract 1.42."},{"key":"997_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.950171","volume":"13","author":"KL Makridis","year":"2022","unstructured":"Makridis KL, Bast T, Prager C, Kovacevic-Preradovic T, Bittigau P, Mayer T, et al. Real-world experience treating pediatric epilepsy patients with cenobamate. Front Neurol. 2022;13:950171. https:\/\/doi.org\/10.3389\/fneur.2022.950171.","journal-title":"Front Neurol"},{"key":"997_CR85","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.seizure.2022.10.004","volume":"102","author":"E Schuetz","year":"2022","unstructured":"Schuetz E, Wagner K, Metternich B, Papadopoulou G, Kravalis K, Heers M, et al. Effects of cenobamate on cognitive performance of epilepsy patients. Seizure. 2022;102:129\u201333. https:\/\/doi.org\/10.1016\/j.seizure.2022.10.004.","journal-title":"Seizure"},{"key":"997_CR86","doi-asserted-by":"publisher","unstructured":"Witt J-A, Badr M, Surges R, von Wrede R, Helmstaedter C. Negative impact of cenobamate on cognition: dose-dependent and independent effects. medRxiv. 2024:2024.12.23.24319533.https:\/\/doi.org\/10.1101\/2024.12.23.24319533","DOI":"10.1101\/2024.12.23.24319533"},{"key":"997_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109605","volume":"151","author":"GL Krauss","year":"2024","unstructured":"Krauss GL, Chung SS, Ferrari L, Stern S, Rosenfeld WE. Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies. Epilepsy Behav. 2024;151:109605. https:\/\/doi.org\/10.1016\/j.yebeh.2023.109605.","journal-title":"Epilepsy Behav"},{"key":"997_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2025.03.012","volume":"129","author":"Z Vlakou","year":"2025","unstructured":"Vlakou Z, Keramida A, Kotsali-Peteinelli V, Matsingos A, Konstantinidi M, Chondrogianni M, et al. Cenobamate in developmental and epileptic encephalopathies and generalized epilepsies: a case report on epilepsy with myoclonic-atonic seizures and systematic review of current evidence. Seizure. 2025;129:1\u20138. https:\/\/doi.org\/10.1016\/j.seizure.2025.03.012.","journal-title":"Seizure"},{"key":"997_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107796","volume":"116","author":"R Elizebath","year":"2021","unstructured":"Elizebath R, Zhang E, Coe P, Gutierrez EG, Yang J, Krauss GL. Cenobamate treatment of focal-onset seizures: quality of life and outcome during up to eight years of treatment. Epilepsy Behav. 2021;116:107796. https:\/\/doi.org\/10.1016\/j.yebeh.2021.107796.","journal-title":"Epilepsy Behav"},{"issue":"5","key":"997_CR90","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s40120-024-00651-4","volume":"13","author":"KD Laxer","year":"2024","unstructured":"Laxer KD, Elder CJ, Di Gennaro G, Ferrari L, Krauss GL, Pellinen J, et al. Presurgical use of cenobamate for adult and pediatric patients referred for epilepsy surgery: expert panel recommendations. Neurol Ther. 2024;13(5):1337\u201348. https:\/\/doi.org\/10.1007\/s40120-024-00651-4.","journal-title":"Neurol Ther"},{"issue":"6","key":"997_CR91","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70229","volume":"32","author":"L Hogeveen","year":"2025","unstructured":"Hogeveen L, Legros B, Meurs A, De Herdt V, Sprengers M, Hodl S, et al. The effectiveness of cenobamate in patients treated with vagus nerve stimulation for drug resistant epilepsy. Eur J Neurol. 2025;32(6):e70229. https:\/\/doi.org\/10.1111\/ene.70229.","journal-title":"Eur J Neurol"},{"issue":"9","key":"997_CR92","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16348","volume":"31","author":"G Atanasio","year":"2024","unstructured":"Atanasio G, Germano A, Granata F, Tomaiuolo F, Labate A. A case of frontal lobe seizures with \u201cdancing-like\u201d semiology. Eur J Neurol. 2024;31(9):e16348. https:\/\/doi.org\/10.1111\/ene.16348.","journal-title":"Eur J Neurol"},{"key":"997_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2025.107647","volume":"218","author":"S Aboumatar","year":"2025","unstructured":"Aboumatar S, Gavvala JR, Jaisani Z, Kuzniecky R, Privitera M, Ring M, et al. Electrographic seizures on responsive neurostimulation: an early and objective measure of response to cenobamate. Epilepsy Res. 2025;218:107647. https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107647.","journal-title":"Epilepsy Res"},{"key":"997_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106952","volume":"184","author":"B Abou-Khalil","year":"2022","unstructured":"Abou-Khalil B, Aboumatar S, Klein P, Krauss GL, Sperling MR, Rosenfeld WE. Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsy Res. 2022;184:106952. https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106952.","journal-title":"Epilepsy Res"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00997-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00997-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00997-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:03:25Z","timestamp":1790381005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00997-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":94,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["997"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00997-x","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"22 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following conflicts of interest. Giancarlo Di Gennaro has received speaker\u2019s honoraria from UCB Pharma, Eisai, Lusofarmaco, LivaNova, and Angelini Pharma, and has served on advisory boards for Angelini Pharma, LivaNova, and UCB Pharma. Carlo Di Bonaventura has received speaker\u2019s or consultancy fees from Eisai, UCB Pharma, Jazz Pharmaceuticals, Angelini Pharma, and Lusofarmaco, and has participated in advisory boards for Eisai, UCB Pharma, Jazz Pharmaceuticals, BIAL, and Angelini Pharma. Carlo Andrea Galimberti and Alfonso Iudice declare no conflicts of interest related to this work. Simona Lattanzi has received speaker's or consultancy fees from Angelini Pharma, Eisai, GW Pharmaceuticals, Hikma Pharmaceuticals, NewBridge Pharmaceuticals, and UCB Pharma and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, BIAL, Eisai, GW Pharmaceuticals, Hikma Pharmaceuticals, Rapport Therapeutics, and UCB Pharma outside the submitted work. Simona Lattanzi is an Editorial Board member of Neurology and Therapy. Simona Lattanzi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based exclusively on previously published studies and does not report any new study involving human participants or animals performed by any of the authors. Ethics committee approval and informed consent were therefore not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}